Editas Medicine, Inc.

EDIT

$3.05

-0.97%

2026-09-03 11:49:39 EDT-$0.03

Healthcare

Biotechnology

NASDAQ

Active Trading

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. ...

Price Action of EDIT

$3.05

-0.97%-$0.03

High—

Low—

52W High-32.8%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Editas Medicine, Inc. is a leading clinical-stage genome editing company headquartered in Cambridge, Massachusetts. Founded in November 2013 by pioneers in the field, including Feng Zhang and Jennifer Doudna, the company was originally known as Gengine, Inc. before adopting its current name in the same year. The company leverages its ...Editas Medicine, Inc. is a leading clinical-stage genome editing company headquartered in Cambridge, Massachusetts. Founded in November 2013 by pioneers in the field, including Feng Zhang and Jennifer Doudna, the company was originally known as Gengine, Inc. before adopting its current name in the same year. The company leverages its proprietary CRISPR/Cas9 and CRISPR/Cas12a platforms to develop in vivo and ex vivo therapies. Its lead program, EDIT-401, aims to reduce LDL cholesterol for hyperlipidemia by upregulating the LDL receptor. Additionally, the company is developing therapies for sickle cell disease and transfusion-dependent beta thalassemia, as well as exploring in vivo editing for other tissues. Editas also collaborates with Juno Therapeutics to develop alpha-beta T-cell medicines for cancer and autoimmune diseases. As of recent reports, the company employs around 226 people and has a market capitalization of approximately $440 million. Financially, Editas is in a pre-revenue stage, with R&D expenses significantly outpacing revenue, resulting in negative profitability and cash flow, yet it maintains a strong cash position to fund its pipeline. Under the leadership of CEO Gilmore O'Neill, the company continues to advance its scientific research, aiming to deliver one-time curative therapies to patients. Despite financial losses typical for clinical-stage biotech firms, Editas remains a key player in the gene editing space with significant intellectual property and strategic partnerships.ExpandCollapse

Founded

2013

Employees

CEO

Gilmore O'Neill

Full Name

Editas Medicine, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-196.63%

Market Cap

$0.47B

Current Ratio

3.19

WACC

12.90%

ROIC

-43.78%

Contact Information

https://www.editasmedicine.com

617 401 9000

11 Hurley Street, Cambridge, MA 02141

Key Metrics of EDIT

Snapshot

Latest / TTM · 6 periods

Market Cap

$468.06M

ROCE

-48.6%

EV / EBITDA

-4.36x

+22.2% YoY

FCF Yield

-25.5%

+65.7% YoY

Cash Conversion Cycle

-64.3d

Current Ratio

3.19

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of EDIT

Profitability trend

Latest / TTM · 6 periods

Gross Margin

56.9%

Net Margin

-157.3%

P/E Ratio

-4.12x

n/a

Debt / Equity

0.15

n/a

Current Ratio

3.19

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of EDIT

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.19 · Revenue $4.49M · 6 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.18 · Revenue $6.66M · 5 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.78 · Revenue $25.89M · 8 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.18 · Revenue $3.13M · 3 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $-0.15 · Revenue $11.89M
View filing
May 5, 2026
Q1 FY2026 · Results reported
EPS $-0.26 · Revenue $2.83M
View filing
Mar 9, 2026
FY2025 · Annual results
EPS $-1.80 · Revenue $40.52M
View filing
Nov 10, 2025
Q3 FY2025 · Results reported
EPS $-0.28 · Revenue $7.54M
View filing
Aug 12, 2025
Q2 FY2025 · Results reported
EPS $-0.63 · Revenue $3.58M
View filing
May 12, 2025
Q1 FY2025 · Results reported
EPS $-0.92 · Revenue $4.66M
View filing

Financial Statements of EDIT

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$40.5M	+25.4%	+320.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-160.1M	+32.5%	+27.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+100.0%	+119.4%	+20.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-245.2%	+68.5%	+82.3%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-395.0%	+46.2%	+82.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-165.8M	+24.3%	-28.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-409.3%	+39.6%	+69.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	281.1%	+977.4%	-99.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.54x	-5.4%	-1.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$186.5M	-45.4%	+58.9%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.80 vs -1.98	+9.0%	-0.15 vs -0.27	+44.5%
Revenue Surprise	$40.5M vs $24.1M	+67.9%	$11.9M vs $2.8M	+317.7%

Insider Transactions of EDIT

Acquisitions (A)

Since Jun 3, 2026

Disposals (D)

Since Jun 3, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 6, 2026	Ellinor Patrick Thomas II	director	Stock Option (right to buy)	A	103,400	$2.90
Aug 6, 2026	Ellinor Patrick Thomas II	director:	—	—	0	—
Aug 3, 2026	Parison Amy	officer: SVP, Chief Financial Officer	Common Stock	D	678	$2.58
Jul 28, 2026	Burkly Linda	officer: EVP, CHIEF SCIENTIFIC OFFICER	Common Stock	D	4,928	$2.67
Jun 17, 2026	Connaughton Bernadette	director	Stock Option (right to buy)	A	51,700	$2.55

Leadership Team of EDIT

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Gilmore O'Neill	President, Chief Executive Officer & Director	USD 1,070,718	—	1964	Active
Linda C. Burkly	Executive Vice President & Chief Scientific Officer	USD 734,972	—	1957	Active
Amy Parison	Senior Vice President & Chief Financial Officer	USD 555,520	Female	1986	Active
Feng Zhang	Co-Founder & Scientific Advisory Board Member	—	—	—	Active
George McDonald Church	Co-Founder & Scientific Advisory Board Member	—	—	1954	Active
Frank Panaccio	Senior Vice President & Chief Business Officer	—	Male	—	Active
Damien Grierson	Senior Vice President, General Counsel & Corporate Secretary	—	Male	—	Active
Tom Love	Vice President of People	—	Male	—	Active
Brieana Buckley	Senior Vice President of Development and Program Leadership	—	Female	—	Active
Gregory Whitehead	Executive Vice President and Chief Technical & Quality Officer	—	Male	—	Active

Recent News of EDIT

Zacks Investment Research8/10/2026Neutral

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

GlobeNewsWire8/5/2026Neutral

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates Recent financing strengthens Company's capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the second quarter 2026 and provided business updates.

GlobeNewsWire8/4/2026Neutral

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic

Forbes6/17/2026Neutral

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Fool - Investing News5/31/2026Neutral

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Historical Employee Count of EDIT

Current

Change

-64.63%

Minimum

Maximum

265

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	87	10-K	Mar 9, 2026	View
Dec 31, 2024	246	10-K	Mar 5, 2025	View
Dec 31, 2023	265	10-K	Feb 28, 2024	View
Dec 31, 2022	226	10-K	Feb 22, 2023	View
Dec 31, 2021	264	10-K	Feb 24, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Editas Medicine, Inc.